Moreover, a multicenter randomized phase II trial evaluated the safety, tolerability, and toxicity profile of trastuzumab in patients with HER2 advanced or recurrent endometrial carcinoma, and observed that trastuzumab appears to be safe and has a manageable toxicity profile both when used in combination with chemotherapy and when used as monotherapy [41]. The gene discussed is ERBB2; the disease is endometrial carcinoma.